Sonus Networks Inc. (NASDAQ:SONS) As of this writing is up (+10.77%) on 3,429,966 shares traded.
From November 30th's Low of $1.57 per share to today's High of $2.22, Sonus Networks Inc. (NASDAQ:SONS) is up 41%.
Sonus Networks, Inc. provides infrastructure and subscriber solutions. It offers session border control (SBC), voice over Internet protocol (VoIP), and access and VoIP media gateway solutions that allow the delivery of voice and multimedia sessions over IP networks. Its products include Sonus SBC 5200 and Sonus SBC 5100 Session Border Controllers, which provide IP to IP SBC functionality for service providers and enterprise customers; Sonus SBC 9000 Session Border Controller that permits service providers to transform their time division multiplexing networks to IP; PSX Policy & Routing Server, which translates business policies into actual call control, routing, and service selection decisions; GSX9000 Open Services Switch that enables voice traffic to be transported over packet networks; GSX4000 Open Services Switch; and ASX Call Feature Server that provides local area calling and regulatory features for residential and enterprise markets. The company also offers Network Analytics Suite of performance management products, including NetScore network performance analysis tool, NetAssure voice quality monitoring tool, and NetEng network audit and visualization engine that are used for the collection, monitoring, reporting, and notification of performance metrics.
Growing Stock Report is Adding SONS Sonus Networks Inc. (NASDAQ:SONS) to it's Communication Equipment Watch List.
Get Poll & SONS Consensus Report Here: http://www.growingstockreport.com/Survey.aspx?stock=SONS
Amicus Therapeutics, Inc.(NASDAQ:FOLD) As of this writing is up (+17.25%) on 2,552,472 shares traded. From of Yesterday's Low $2.67 to Today's High of $3.44, Amicus Therapeutics, Inc.(NASDAQ:FOLD) moved up 28.84%.
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered, small molecule drugs for the treatment of lysosomal storage disorders and diseases of neurodegeneration. Its drugs are known as pharmacological chaperones, which selectively bind to the target protein, enhance the stability of the protein, help it fold into the three-dimensional shape, as well as allow proper trafficking of the protein, thereby increasing protein activity, enhance cellular function, and reduce cell stress.
Growing Stock Report is Adding Amicus Therapeutics, Inc.(NASDAQ:FOLD) to it's Healthcare Sector Watch List.
Get Poll & FOLD Consensus Report Here: http://www.growingstockreport.com/Survey.aspx?stock=FOLD
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks. Simply sign up for free and start receiving exclusive alerts. Subscribe Here: http://www.GrowingStockReport.com
Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Contact Info: Growing Stock Reporteditor@GrowingStockReport.com